The estimated Net Worth of Thomas M. Hagedorn is at least $15.5 Milión dollars as of 22 February 2012. Thomas Hagedorn owns over 10,000 units of Electromed stock worth over $15,421,770 and over the last 14 years Thomas sold ELMD stock worth over $30,000.
Thomas has made over 2 trades of the Electromed stock since 2011, according to the Form 4 filled with the SEC. Most recently Thomas bought 10,000 units of ELMD stock worth $30,100 on 22 February 2012.
The largest trade Thomas's ever made was buying 10,000 units of Electromed stock on 22 February 2012 worth over $30,100. On average, Thomas trades about 6,667 units every 94 days since 2010. As of 22 February 2012 Thomas still owns at least 874,250 units of Electromed stock.
You can see the complete history of Thomas Hagedorn stock trades at the bottom of the page.
Thomas's mailing address filed with the SEC is C/O ELECTROMED, INC., 500 SIXTH STREET NW, NEW PRAGUE, MN, 56071.
Over the last 14 years, insiders at Electromed have traded over $2,585,226 worth of Electromed stock and bought 684,801 units worth $2,582,707 . The most active insiders traders include Oak Partners, Llc Red, Stephen H. Craney a Kathleen Skarvan. On average, Electromed executives and independent directors trade stock every 84 days with the average trade being worth of $358,798. The most recent stock trade was executed by James L. Cunniff on 1 March 2024, trading 9,000 units of ELMD stock currently worth $137,250.
electromed, inc. is a minnesota-based company (nyse mkt: elmd) and the innovative leader in the development, manufacture, and worldwide sales of the smartvest® airway clearance system. the patented system uses high frequency chest wall oscillation (hfcwo), a better-tolerated alternative to chest physiotherapy (cpt), to deliver vigorous, yet comfortable airway clearance treatment for patients battling the consequences of retained secretions. hfcwo has been clinically proven to clear the lungs of excess mucus, improve and reduce lung infections for individuals suffering from various conditions including atelectasis, copd, bronchiectasis, neuromuscular diseases, and cystic fibrosis. electromed, inc. is accredited by the joint commission and is iso 13485:2003 and iso 9001:2008 certified.
Electromed executives and other stock owners filed with the SEC include: